Stem cell specialist ReNeuron Group plc is aiming to raise up to £3 million via a placing of up to 100 million new shares, providing the hard-up company with sufficient working capital for at least the next 12 months.
The money will fund the Phase I trial of ReN001, ReNeuron’s foetal neural stem cell product, in the treatment of stroke. The trial was approved by UK regulators in January.
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
Sign up for the Funding Newswire
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
